Renin-angiotensin system blockers increase risk of angio-oedema
- Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psichology, University of Rome Sapienza, Sant'Andrea Hospital, Italy, and IRCCS Neuromed, Pozzilli (IS), Italy
- Correspondence to: Professor Massimo Volpe
Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psichology, University of Rome Sapienza, Sant'Andrea Hospital, via di Grottarossa 1035, Rome 00189, Italy;
Commentary on: Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582–9.
Hypertension continues to represent a major threat for people's health because it is associated with raised cardiovascular (CV) morbidity and mortality.1 As a consequence of the threatening role of hypertension, antihypertensive therapy has become one of the cornerstones of any CV prevention strategy. Solid evidence has accumulated over the last two decades of the beneficial role of renin-angiotensin system (RAS) blocking agents, including ACE inhibitors, angiotensin receptor blockers (ARBs) and, recently, direct renin inhibitors (DRIs), for not only lowering blood pressure, but also in reducing hypertension-related burden of disease.
Beside the differences …